ClinicalTrials.gov record
Active, not recruiting Phase 1 Interventional

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT05599984

Public ClinicalTrials.gov record NCT05599984. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 5:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors

Study identification

NCT ID
NCT05599984
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
AbbVie
Industry
Enrollment
288 participants

Conditions and interventions

Interventions

  • ABBV-706 Drug
  • Budigalimab Drug
  • Carboplatin Drug
  • Cisplatin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 4, 2022
Primary completion
Oct 31, 2027
Completion
Oct 31, 2027
Last update posted
May 6, 2026

2022 – 2027

United States locations

U.S. sites
22
U.S. states
17
U.S. cities
21
Facility City State ZIP Site status
Banner MD Anderson Cancer Ctr /ID# 260129 Gilbert Arizona 85234
City Of Hope Comprehensive Cancer Center /ID# 271295 Duarte California 91030
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 259884 Irvine California 92618
Yale New Haven Hospital /ID# 246647 New Haven Connecticut 06510
Georgetown University Hospital /ID# 255352 Washington D.C. District of Columbia 20007
University of Chicago Medical Center /ID# 256334 Chicago Illinois 60637
Fort Wayne Medical Oncology and Hematology, Inc /ID# 260130 Fort Wayne Indiana 46804
University of Iowa Hospitals and Clinics /ID# 246638 Iowa City Iowa 52242
Barbara Ann Karmanos Cancer In /ID# 261799 Detroit Michigan 48201
Henry Ford Hospital /ID# 246648 Detroit Michigan 48202
START Midwest /ID# 251257 Grand Rapids Michigan 49546-7062
St. Lukes Hosp. of Kansas City /ID# 259958 Kansas City Missouri 64111
Washington University-School of Medicine /ID# 246286 St Louis Missouri 63110
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 246303 New York New York 10065-6007
Duke Cancer Center /ID# 246285 Durham North Carolina 27710
UH Cleveland Medical Center /ID# 246641 Cleveland Ohio 44106
Univ Oklahoma HSC /ID# 250884 Oklahoma City Oklahoma 73117
Tennessee Oncology, PLLC /ID# 246283 Nashville Tennessee 37203
University of Texas MD Anderson Cancer Center /ID# 246287 Houston Texas 77030
South Texas Accelerated Research Therapeutics /ID# 248946 San Antonio Texas 78229
University of Utah /ID# 246640 Salt Lake City Utah 84112-5500
Northwest Medical Specialties - Tacoma /ID# 262801 Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05599984, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 6, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05599984 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →